Eliminate NAFTA 2.0 Terms that Lock in High Drug Prices
U.S. Congress Members
The North American Free Trade Agreement has been catastrophic for working families, resulting in lower wages and outsourced jobs. But the renegotiated NAFTA 2.0—now called the U.S.-Mexico-Canada Agreement—still doesn’t do enough to protect working people.
What we need in a free trade agreement is strong enforcement regarding labor and the environment. We need the next NAFTA to completely eliminate investor-state dispute settlement, the private court system that helps corporations over workers. And we need the new deal to stop undermining public interest regulation. None of these are accomplished in the new proposal.
The biggest giveaway of all in the USMCA is to pharmaceutical companies: The deal would lock in outrageously high U.S. medicine prices by creating barriers and delays to affordable generics and biosimilars. We can’t have Trump’s deal actually ensure that Americans pay too much for our drugs.
Tell Congress that the Big Pharma giveaways must be eliminated from the revised NAFTA deal.
Sponsored by
To:
U.S. Congress Members
From:
[Your Name]
The revised NAFTA deal—the U.S.-Mexico-Canada Agreement—that Donald Trump signed lacks strong labor and environmental enforcement, fails to completely eliminate investor-state dispute settlement, and continues to undermine strong public interest regulation. On top of all that, it would lock in high U.S. medicine prices. Big Pharma rigged the rules: USMCA (NAFTA 2.0) guarantees extended monopoly rights for pharmaceutical corporations to block generic competition.
This would tie the hands of Congress—now and in the future—when it comes to changing the policies that lead to high drug prices. It also would export these bad policies to Mexico and Canada. We call on Congress to ensure that Trump removes the Big Pharma giveaways from the text of USMCA before Congress begins consideration of the deal.